Name: José Almeida
New title: CEO, Hologic
Previous title: CEO, Baxter
Hologic has appointed José Almeida as CEO, putting the former Baxter leader in charge of the company as it starts life as a privately owned business.
On Monday, Hologic said Steve MacMillan would retire as CEO once Blackstone and TPG closed their $18.3 billion deal to take the women’s health company private. The investors completed the takeover Tuesday. In connection with closing the deal, Hologic revealed it has appointed Almeida as CEO with immediate effect.
Almeida retired as Baxter CEO in February 2025. During Almeida’s time as CEO, Baxter bought Hillrom for $10.5 billion and divested its biopharma solutions and kidney care businesses. The deals were part of an attempt to increase Baxter’s focus on higher-growth markets.
Hologic ended last year with $2.17 billion in cash and cash equivalents. At a meeting last year to discuss an offer to buy the business, Hologic’s board said that the company had a “strong balance sheet to fund growth initiatives, such as innovation and acquisitions.” The board also noted the underperformance of medtech stocks and the potential for investors’ focus on short-term financials to hinder strategic actions.
Blackstone and TPG have yet to publicly discuss their plans for Hologic in detail. Hologic’s press release about Almeida’s appointment noted his leadership of Baxter’s strategic repositioning, including a focus on operational improvement, portfolio changes and medical product innovation.
